Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 2
1999 2
2000 3
2001 1
2002 4
2003 3
2004 6
2005 3
2006 4
2007 3
2008 3
2009 5
2010 1
2012 3
2013 1
2014 8
2015 2
2016 8
2017 4
2018 6
2019 6
2020 4
2021 6
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

83 results
Results by year
Filters applied: . Clear all
Page 1
The evolution of brachytherapy for prostate cancer.
Zaorsky NG, Davis BJ, Nguyen PL, Showalter TN, Hoskin PJ, Yoshioka Y, Morton GC, Horwitz EM. Zaorsky NG, et al. Nat Rev Urol. 2017 Jun 30;14(7):415-439. doi: 10.1038/nrurol.2017.76. Nat Rev Urol. 2017. PMID: 28664931 Free PMC article. Review.
Brachytherapy (BT), using low-dose-rate (LDR) permanent seed implantation or high-dose-rate (HDR) temporary source implantation, is an acceptable treatment option for select patients with prostate cancer of any risk group. ...The 5-year freedom from biochemical fail
Brachytherapy (BT), using low-dose-rate (LDR) permanent seed implantation or high-dose-rate (HDR) temporary source implantation, is a
Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis.
Wallis CJD, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R, Shah PS, Danjoux C, Nam RK. Wallis CJD, et al. Eur Urol. 2016 Jul;70(1):21-30. doi: 10.1016/j.eururo.2015.11.010. Epub 2015 Dec 15. Eur Urol. 2016. PMID: 26700655 Free article. Review.
CONTEXT: To date, there is no Level 1 evidence comparing the efficacy of radical prostatectomy and radiotherapy for patients with clinically-localized prostate cancer. OBJECTIVE: To conduct a meta-analysis assessing the overall and prostate cancer-specific mortality …
CONTEXT: To date, there is no Level 1 evidence comparing the efficacy of radical prostatectomy and radiotherapy for patients with clinically …
A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).
Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, Reiter RE, Rettig M, Calais J, Nickols NG, Dess RT, Spratt DE, Steinberg ML, Nguyen PL, Davis BJ, Zaorsky NG, Kishan AU. Valle LF, et al. Eur Urol. 2021 Sep;80(3):280-292. doi: 10.1016/j.eururo.2020.11.010. Epub 2020 Dec 11. Eur Urol. 2021. PMID: 33309278 Review.
Severe GU toxicity was significantly lower with all three forms of radiotherapeutic salvage than with RP (adjusted rates of 20% after RP vs 5.6%, 9.6%, and 9.1% after SBRT, HDR brachytherapy, and LDR brachytherapy, respectively; p 0.001 for all). ...CONCLUSIONS: Lar …
Severe GU toxicity was significantly lower with all three forms of radiotherapeutic salvage than with RP (adjusted rates of 20% after RP vs …
Low dose rate prostate brachytherapy.
Stish BJ, Davis BJ, Mynderse LA, McLaren RH, Deufel CL, Choo R. Stish BJ, et al. Transl Androl Urol. 2018 Jun;7(3):341-356. doi: 10.21037/tau.2017.12.15. Transl Androl Urol. 2018. PMID: 30050795 Free PMC article. Review.
Low dose rate (LDR) prostate brachytherapy is an evidence based radiation technique with excellent oncologic outcomes. ...In addition to reviewing technical aspects and reported clinical outcomes of LDR prostate brachytherapy, this article will focus o …
Low dose rate (LDR) prostate brachytherapy is an evidence based radiation technique with excellent oncologic outcomes. ...In a …
Brachytherapy in the Management of Prostate Cancer.
Stish BJ, Davis BJ, Mynderse LA, Deufel CL, Choo R. Stish BJ, et al. Surg Oncol Clin N Am. 2017 Jul;26(3):491-513. doi: 10.1016/j.soc.2017.01.008. Epub 2017 May 11. Surg Oncol Clin N Am. 2017. PMID: 28576185 Review.
Brachytherapy is performed by directly inserting radioactive sources into the prostate gland and is an important treatment option for appropriately selected men with prostate adenocarcinoma. ...This article highlights some important considerations and publish
Brachytherapy is performed by directly inserting radioactive sources into the prostate gland and is an important treatment opt
Development and Preliminary Evaluation of an Anthropomorphic Trans-rectal Ultrasound Prostate Brachytherapy Training Phantom.
Doyle AJ, Sullivan F, Walsh J, King DM, Cody D, Browne JE. Doyle AJ, et al. Ultrasound Med Biol. 2021 Mar;47(3):833-846. doi: 10.1016/j.ultrasmedbio.2020.11.020. Epub 2021 Jan 7. Ultrasound Med Biol. 2021. PMID: 33358053
The quality of the trans-rectal ultrasound (TRUS) image, and thus seed placement during the prostate brachytherapy (PBT) procedure, relies on the user's technical and clinical competency. ...TRUS clinical patient data informed the design of 3-D printed moulds to fab …
The quality of the trans-rectal ultrasound (TRUS) image, and thus seed placement during the prostate brachytherapy (PBT) proce …
Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.
Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Valle L, Chong N, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Klein EA, Tosoian JJ, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Kupelian PA, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Kishan AU. Philipson RG, et al. Eur Urol. 2021 Aug;80(2):142-146. doi: 10.1016/j.eururo.2021.04.035. Epub 2021 May 10. Eur Urol. 2021. PMID: 33985797
The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecu …
The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical cour …
ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer.
Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. Hsu IC, et al. Brachytherapy. 2014 Jan-Feb;13(1):27-31. doi: 10.1016/j.brachy.2013.11.007. Epub 2013 Dec 22. Brachytherapy. 2014. PMID: 24368283 Review.
PURPOSE: High-dose-rate (HDR) brachytherapy plays a potential curative role in the treatment of prostate cancer. ...CONCLUSIONS: In combining available medical literature and expert opinion, this manuscript may serve as an aid for other practitioners in the appropri …
PURPOSE: High-dose-rate (HDR) brachytherapy plays a potential curative role in the treatment of prostate cancer. ...CONCLUSION …
Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.
Routman DM, Funk RK, Stish BJ, Mynderse LA, Wilson TM, McLaren R, Harmsen WS, Mara K, Deufel CL, Furutani KM, Haddock MG, Pisansky TM, Choo CR, Davis BJ. Routman DM, et al. Brachytherapy. 2019 Jan-Feb;18(1):1-7. doi: 10.1016/j.brachy.2018.09.003. Epub 2018 Oct 4. Brachytherapy. 2019. PMID: 30293836
CONCLUSIONS: LDR brachytherapy provided excellent outcomes in this large series of patients treated for localized organ-confined prostate cancer. ...Primary Gleason 4 disease was also predictive of distant metastases and decreased prostate cancer-specific sur …
CONCLUSIONS: LDR brachytherapy provided excellent outcomes in this large series of patients treated for localized organ-confined p
Surveillance after prostate focal therapy.
Tay KJ, Amin MB, Ghai S, Jimenez RE, Kench JG, Klotz L, Montironi R, Muto S, Rastinehad AR, Turkbey B, Villers A, Polascik TJ. Tay KJ, et al. World J Urol. 2019 Mar;37(3):397-407. doi: 10.1007/s00345-018-2363-y. Epub 2018 Jun 9. World J Urol. 2019. PMID: 29948045 Review.
INTRODUCTION: Long-term outcomes from large cohorts are not yet available upon which to base recommended follow-up protocols after prostate focal therapy. This is an updated summary of a 2015 SIU-ICUD review of the best available current evidence and expert consensus on gu …
INTRODUCTION: Long-term outcomes from large cohorts are not yet available upon which to base recommended follow-up protocols after prosta
83 results